(These) 'adaptive approaches are all based on the premise that knowledge about medicines is not binary but continues to evolve over time. The proposal is to replace the single transition from non-approval to approval with a series of approval stages with iterative phases of evidence gathering and regulatory evaluation.' 

Source: WHO- Priority Medicines for Europe and the World 2013 Update 

Adaptive Licensing

Source: ​Hans Eichler, EMA, on Adaptive Licensing in March 2012

Surviving Melanoma in Europe.  

Access to prevention, early detection and effective treatment for all.

Melanoma Patient Network Europe